Risk of COVID 19 in patients with inflammatory bowel diseases compared to a control population.
COVID-19
Inflammatory bowel disease
Symptoms
Journal
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
ISSN: 1878-3562
Titre abrégé: Dig Liver Dis
Pays: Netherlands
ID NLM: 100958385
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
05
08
2020
revised:
12
12
2020
accepted:
15
12
2020
pubmed:
24
1
2021
medline:
12
3
2021
entrez:
23
1
2021
Statut:
ppublish
Résumé
It is unclear whether patients with inflammatory bowel disease (IBD) are at increased risk of COVID-19. This observational study compared the prevalence of COVID-19 symptoms, diagnosis and hospitalization in IBD patients with a control population with non-inflammatory bowel disorders. This multicentre study, included 2733 outpatients (1397 IBD patients and 1336 controls), from eight major gastrointestinal centres in Lombardy, Italy. Patients were invited to complete a web-based questionnaire regarding demographic, historical and clinical features over the previous 6 weeks. The prevalence of COVID-19 symptoms, diagnosis and hospitalization for COVID-19 was assessed. 1810 patients (64%) responded to the questionnaire (941 IBD patients and 869 controls). IBD patients were significantly younger and of male sex than controls. NSAID use and smoking were more frequent in controls. IBD patients were more likely treated with vitamin-D and vaccinated for influenza. Highly probable COVID-19 on the basis of symptoms and signs was less frequent in the IBD group (3.8% vs 6.3%; OR:0.45, 95%CI:0.28-0.75). IBD patients had a lower rate of nasopharyngeal swab-PCR confirmed diagnosis (0.2% vs 1.2%; OR:0.14, 95%CI:0.03-0.67). There was no difference in hospitalization between the groups (0.1% vs 0.6%; OR:0.14, 95%CI:0.02-1.17). IBD patients do not have an increased risk of COVID-19 specific symptoms or more severe disease compared with a control group of gastroenterology patients.
Sections du résumé
BACKGROUND
It is unclear whether patients with inflammatory bowel disease (IBD) are at increased risk of COVID-19.
OBJECTIVES
This observational study compared the prevalence of COVID-19 symptoms, diagnosis and hospitalization in IBD patients with a control population with non-inflammatory bowel disorders.
METHODS
This multicentre study, included 2733 outpatients (1397 IBD patients and 1336 controls), from eight major gastrointestinal centres in Lombardy, Italy. Patients were invited to complete a web-based questionnaire regarding demographic, historical and clinical features over the previous 6 weeks. The prevalence of COVID-19 symptoms, diagnosis and hospitalization for COVID-19 was assessed.
RESULTS
1810 patients (64%) responded to the questionnaire (941 IBD patients and 869 controls). IBD patients were significantly younger and of male sex than controls. NSAID use and smoking were more frequent in controls. IBD patients were more likely treated with vitamin-D and vaccinated for influenza. Highly probable COVID-19 on the basis of symptoms and signs was less frequent in the IBD group (3.8% vs 6.3%; OR:0.45, 95%CI:0.28-0.75). IBD patients had a lower rate of nasopharyngeal swab-PCR confirmed diagnosis (0.2% vs 1.2%; OR:0.14, 95%CI:0.03-0.67). There was no difference in hospitalization between the groups (0.1% vs 0.6%; OR:0.14, 95%CI:0.02-1.17).
CONCLUSION
IBD patients do not have an increased risk of COVID-19 specific symptoms or more severe disease compared with a control group of gastroenterology patients.
Identifiants
pubmed: 33483259
pii: S1590-8658(20)31093-8
doi: 10.1016/j.dld.2020.12.013
pmc: PMC7762705
pii:
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
263-270Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest All authors have indicated they have no potential conflicts of interest relevant to this article to disclose.
Références
Infection. 2021 Apr;49(2):233-239
pubmed: 33034020
J Crohns Colitis. 2020 Sep 16;14(9):1334-1336
pubmed: 32215548
Gastroenterology. 2018 Aug;155(2):337-346.e10
pubmed: 29655835
Gastroenterology. 2020 Aug;159(2):481-491.e3
pubmed: 32425234
Aliment Pharmacol Ther. 2020 Jul;52(2):276-283
pubmed: 32359205
BMJ. 2020 Mar 23;368:m1168
pubmed: 32205306
Otolaryngol Head Neck Surg. 2020 Jul;163(1):114-120
pubmed: 32423357
Math Biosci. 2020 Jul;325:108378
pubmed: 32507746
Tob Induc Dis. 2020 Mar 20;18:20
pubmed: 32206052
PLoS One. 2015 Jul 14;10(7):e0132838
pubmed: 26172441
Gastroenterology. 2021 Apr;160(5):1877-1878
pubmed: 32407807
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Med Hypotheses. 2020 Apr 22;140:109752
pubmed: 32361099
Therapie. 2020 Jul - Aug;75(4):355-362
pubmed: 32418728
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Aliment Pharmacol Ther. 2020 Jun;51(12):1434-1437
pubmed: 32311755
Chest. 2020 Jul;158(1):55-56
pubmed: 32243944
Aliment Pharmacol Ther. 2020 Jul;52(1):54-72
pubmed: 32348598
Autoimmun Rev. 2020 Jul;19(7):102574
pubmed: 32376399
Ear Nose Throat J. 2020 Nov;99(9):577-578
pubmed: 32436441
Gastroenterology. 2020 Oct;159(4):1541-1544.e2
pubmed: 32479824
Pathogens. 2020 Mar 04;9(3):
pubmed: 32143502
Eur J Gastroenterol Hepatol. 2021 Mar 1;33(3):319-324
pubmed: 32501876
J Crohns Colitis. 2014 Jun;8(6):443-68
pubmed: 24613021
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):561-565
pubmed: 32413819
Lancet Public Health. 2020 Jun;5(6):e310
pubmed: 32339478
Gut. 2020 Jul;69(7):1213-1217
pubmed: 32354990
Lancet Infect Dis. 2020 Sep;20(9):1014-1015
pubmed: 32304632
Pharmacol Res. 2020 Jul;157:104849
pubmed: 32360482
Nat Med. 2020 Jul;26(7):1037-1040
pubmed: 32393804
Tob Induc Dis. 2020 May 06;18:37
pubmed: 32382258
BMJ. 2020 Mar 17;368:m1086
pubmed: 32184201
Gastroenterology. 2020 Jul;159(1):371-372
pubmed: 32247695
Aging Clin Exp Res. 2020 Jul;32(7):1195-1198
pubmed: 32377965
Nicotine Tob Res. 2020 Aug 24;22(9):1653-1656
pubmed: 32399563